USA flag logo/image

An Official Website of the United States Government

THE COMPLEX 4-CARBOXYPHTHALATO (1, 2-DIAMINOCYCLOHEXANE) PLATINUM (NSC 271674;…

Award Information

Agency:
Department of Health and Human Services 		Branch:
N/A 		Award ID:
4722 		Program Year/Program:
1986 / SBIR
Agency Tracking Number:
4722 		Solicitation Year:
N/A 		Solicitation Topic Code:
N/A 		Solicitation Number:
N/A
Small Business Information
AMT, INC.
508 HEARTWOOD RD CHERRY HILL, NJ 08003 CHERRY HILL, NJ 08003
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 1986
Title: THE COMPLEX 4-CARBOXYPHTHALATO (1, 2-DIAMINOCYCLOHEXANE) PLATINUM (NSC 271674; DACH-PT) HAS UNDERGONE LIMITED CLINICAL TRIALS.
Agency: HHS
Contract: N/A
Award Amount: $50,000.00
 

Abstract:

THE COMPLEX 4-CARBOXYPHTHALATO (1, 2-DIAMINOCYCLOHEXANE) PLATINUM (NSC 271674; DACH-PT) HAS UNDERGONE LIMITED CLINICAL TRIALS. DESIGNED AS AN ALTERNATIVE THERAPY TO CISPLATIN, IT HAS DEMONSTRATED SUBSTANTIALLY REDUCED TOXICITY AND ENHANCED ACTIVITY IN TUMORS RESISTANT TO CISPLATIN IN ANIMALS STUDIES, RESULTS CONFIRMED IN THE CLINIC. HEAVILY PRETREATED PHASE I AND PHASE II PATIENTS RESPONDING TO DACH-PT THERAPY INCLUDED THOSE WITH LUNG, NASOPHARYNGEAL, GASTRIC, OVARIAN, AND BLADDER CANCERS. RENAL AND GASTROINTESTINAL TOXICITY, THE MAJOR SIDE EFFECTS OF CISPLATIN, WERE MINIMAL. EVEN THOUGH THIS COMPLEX POSSESSES OUTSTANDING THERAPEUTIC PROPERTIES, DIFFICULTIES IN PURIFICATION AND AN INHERENT INSTABILITY, RESULTING IN HYDROLYTIC DISSOCIATION, HAVE VIRTUALLY HALTED FURTHER CLINICAL EVALUATIONS ESSENTIAL FOR ITS DEVELOPMENT INTO A COMMERCIALLY AVAILABLE ANTICANCER DRUG. ALL PURIFICATION PROBLEMS HAVE BEEN SOLVED AND BULK QUANTITIES OF THE DRUG HAVE BEEN PREPARED TO ANALYTICAL SPECIFICATIONS FOR CLINICALUSE. IT IS NOW PROPOSED TO ATTEMPT TO STABILIZE THE DRUG BYVARYING TEMPERATURE, PH, BUFFER CONCENTRATION, ETC., IN AN EFFORT TO OBTAIN THE OPTIMUM CONDITIONS IN WHICH THE COMPLEXWILL HAVE ACCEPTABLE STABILITY CHARACTERISTICS WHILE RETAINING ITS SUPERIOR THERAPEUTIC PROPERTIES. SUCCESSFUL STABILIZATION OF DACH-PT SUFFICIENT FOR FORMULATION WILL LEAD TO A DRUG PRODUCT WITH VERY STRONG COMMERCIAL POTENTIAL.

Principal Investigator:

Peter andrulis jr
PRINCIPAL INVESTIGATOR
3016571700

Business Contact:

Small Business Information at Submission:

Andrulis Research Corp
7315 Wisconsin Ave, 650n Bethesda, MD 20814

EIN/Tax ID:
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No